Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 3Phase 2 1

Status

Completed 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 20Thoracic 14Dermatologic 12Breast 10Genitourinary 8Other solid neoplasm 7Tumor-Agnostic 6Lymphoid 6Head & Neck 6Gynecologic 6CNS 5Sarcoma 4Myeloid 2Plasma cell 1Other hematologic neoplasm 1Endocrine 1

Conditions

Neoplasms 4Neoplasm Metastasis 3

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × spartalizumab × Tumor-Agnostic × Clear all
NCT03568058 2026-03-24

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

University of California, San Diego

Phase 1 Completed
25 enrolled 12 charts
Tumor-Agnostic

Neoplasms

NCT05631899 2025-11-24

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1 Active not recruiting
9 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06547957 2025-08-13

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

iTeos Therapeutics

Phase 1 Active not recruiting
55 enrolled
Tumor-Agnostic

Neoplasms

NCT02828098 2024-01-29

Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

Highlight Therapeutics

Phase 1 Completed
44 enrolled
Tumor-Agnostic

Neoplasms

NCT02452268 2023-03-03

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

Novartis

Phase 1 Terminated
83 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03468751 2020-06-01

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Henlix, Inc

Phase 1 Unknown
30 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡